Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate for cognition and motor function in Parkinson's disease (electrophysiological evaluation)
2020-005073-28Phase 2Completed
- Sponsor
- Universidad Rey Juan Carlos
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of methylphenidate in Parkinson's disease (PD) (2 arms), sponsored by Universidad Rey Juan Carlos. Primary endpoint: Reduction of reaction time to predictive and random stimuli after methylphenidate. Started Jun 2021; status: completed.
02
Drugs
methylphenidate
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2020-005073-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005073-28.